Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_assertion type Assertion NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_head.
- NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_assertion description "[The vast majority of colon (80%) and breast (60%) tumors and sarcomas (73%) express CRD-BP whereas in other tumor types, for example prostate carcinomas, its expression is rare.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_provenance.
- NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_assertion evidence source_evidence_literature NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_provenance.
- NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_assertion SIO_000772 12894594 NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_provenance.
- NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_assertion wasDerivedFrom befree-2016 NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_provenance.
- NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_assertion wasGeneratedBy ECO_0000203 NP404099.RAOnl_y9gFWPnzYWe9rPkeEcLexFdWH7D18Qdwc_Efde4130_provenance.